What Are Celldex Therapeutics Inc.'s Key Financial Figures?
| Fiscal year | FY2025 ended December 31, 2025 | FY2024 ended December 31, 2024 | FY2023 ended December 31, 2023 | FY2022 ended December 31, 2022 |
|---|---|---|---|---|
| Revenue | $2 million | $7 million | $7 million | $2 million |
| Operating income | -$287 million | -$195 million | -$155 million | -$115 million |
| Operating margin | -18599.8% | -2778.9% | -2245.3% | -4889.0% |
| Net income | -$259 million | -$158 million | -$141 million | -$112 million |
| Net margin | -16748.0% | -2248.8% | -2054.8% | -4765.6% |
| Operating cash flow | -$211 million | -$158 million | -$107 million | -$104 million |
| Capital expenditures | $3 million | $2 million | $2 million | $2 million |
| Free cash flow | -$214 million | -$160 million | -$109 million | -$106 million |
Operating margin narrowed by 15820.9 percentage points between fiscal 2024 and 2025, which separates pricing and cost discipline from revenue growth alone. Free cash flow (operating cash flow minus capital expenditures) was -$214 million against net income of -$259 million; cash generation covered reported earnings.
What Does Celldex Therapeutics Inc.'s Balance Sheet Show?
| Cash and cash equivalents | $29 million |
|---|---|
| Long-term debt | Not reported |
| Total assets | $583 million |
| Total liabilities | $56 million |
| Shareholders' equity | $527 million |
| Current ratio | 10.5x |
Balance sheet values are as of the end of fiscal 2025. Income statement figures describe a whole year; balance sheet figures describe a single day, so the two answer different questions.
Where These Numbers Come From
Every figure on this page is a value Celldex Therapeutics Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0001104659-26-019652 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 7, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary.
Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation.
Frequently Asked Questions
What was Celldex Therapeutics Inc.'s revenue in fiscal 2025?
Celldex Therapeutics Inc. reported revenue of $2 million for the fiscal year ended December 31, 2025, according to its SEC filings.
What is Celldex Therapeutics Inc.'s operating margin?
Celldex Therapeutics Inc.'s operating margin was -18599.8% in fiscal 2025: operating income of -$287 million on revenue of $2 million.
How much free cash flow did Celldex Therapeutics Inc. generate?
Operating cash flow of -$211 million less capital expenditures of $3 million gives free cash flow of -$214 million for fiscal 2025.